ArticleJournal of cachexia, sarcopenia and muscle2022
Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort.
Article in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Musculoskeletal Disorders.Acta medica Philippina · 2026Article
- Association of SARC-F with muscle mass, strength, and quality derived from bioelectrical impedance spectroscopy for sarcopenia assessment.Scientific reports · 2025Article
- Association between the healthy eating index and sarcopenia in Chinese elderly: a cross-sectional study.BMC geriatrics · 2025Article
- Risk of sarcopenia and mobility of older adults during the COVID-19 pandemic: the longitudinal data from the REMOBILIZE study.Aging clinical and experimental research · 2024Article
- Clinical, functional, and opportunistic CT metrics of sarcopenia at the point of imaging care: analysis of all-cause mortality.Skeletal radiology · 2024Article
- Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18-59 years: a population-based study.Scientific reports · 2023Article
- Racial, Ethnic, and Socioeconomic Differences in a Deficit Accumulation Frailty Index in the Multiethnic Cohort Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2023Article
- Accurate SARC-F Score in Patients with Liver Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Skeletal muscle aging and sarcopenia: Perspectives from mechanical studies of single permeabilized muscle fibers.Journal of biomechanics · 2023Review
- Simplified discriminant parameters for sarcopenia among patients undergoing haemodialysis.Journal of cachexia, sarcopenia and muscle · 2022Article
- Prognostic utility of self-reported sarcopenia (SARC-F) in the Multiethnic Cohort.Journal of cachexia, sarcopenia and muscle · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAge-related loss in skeletal muscle mass, quality, and strength, known as sarcopenia, is a well-known phenomenon of aging and is determined clinically using methods such as dual-energy X-ray absorptiometry (DXA). However, these clinical methods to measure sarcopenia are not practical for population-based studies, and a five-question screening tool known as SARC-F has been validated to screen for sarcopenia.
methodsWe investigated the relationship between appendicular skeletal lean mass/height
resultsIn women, SARC-F score was significantly inversely associated with ALM/HT
conclusionsAn indicator of sarcopenia, determined using SARC-F, showed internal validity against DXA and displayed racial/ethnic and sex differences in distribution. SARC-F was associated with all-cause mortality as well as cause-specific mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.